The development of innovative antifungal agents is essential. Some fungicidal agents are no
longer effective due to resistance development, various side effects, and high toxicity …

Osteoarticular mycoses are chronic debilitating infections that require extended courses of
antifungal therapy and may warrant expert surgical intervention. As there has been no …

Background Chronic pulmonary aspergillosis has a 5-year mortality of 50–80% globally, and
the optimal duration of treatment for chronic pulmonary aspergillosis remains unclear. We …

Aspergillus species are the most frequent cause of fungal infections of the lungs with a
broad spectrum of clinical presentations including invasive pulmonary aspergillosis (IPA) …

Mucormycosis is a deadly opportunistic disease caused by a group of fungus named
mucormycetes. Fungal spores are normally present in the environment and the immune …

Abstract Purpose of Review For this review, we use a One Health approach to examine two
globally emerging public health threats related to antifungal drug resistance: triazole …

Background Whether a combination of glucocorticoid and antifungal triazole is superior to
glucocorticoid alone in reducing exacerbations in patients with allergic bronchopulmonary …

The available antifungal armamentarium consists of only a few drug classes, many limited in
their use by significant toxicities and dangerous drug interactions. Rising opportunistic …

Invasive fungal infections continue to increase as at-risk populations expand. The high
associated morbidity and mortality with fungal diseases mandate the continued investigation …

Isavuconazole is the newest of the clinically available advanced generation triazole
antifungals and is active against a variety of yeasts, molds, and dimorphic fungi. Its current …